Loading clinical trials...
Loading clinical trials...
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.
Conditions
Interventions
RagweedMATAMPL
Locations
4
United States
Michigan Respiratory Health and Research Institute
Novi, Michigan, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
Regional Allergy & Asthma Consultants
Asheville, North Carolina, United States
Lovelace Scientific Resources
Austin, Texas, United States
Start Date
November 1, 2005
Primary Completion Date
August 7, 2006
Completion Date
August 7, 2006
Last Updated
June 11, 2021
Lead Sponsor
Allergy Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions